• 1. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 2. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 3. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 4. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 5. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696

• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Tropane alkaloids Tropane alkaloids
• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Tropane alkaloids

8-Methyl-8-azabicyclo[3.2.1]octan-3-ol hydrochloride (CAS No. 258345-27-6): A Comprehensive Overview

8-Methyl-8-azabicyclo[3.2.1]octan-3-ol hydrochloride, identified by its CAS number 258345-27-6, is a compound of significant interest in the field of pharmaceutical chemistry and medicinal research. This bicyclic azapeptide derivative has garnered attention due to its unique structural features and potential biological activities. The compound’s structure, characterized by a fused bicyclic system containing an azabicyclo[3.2.1]octane core, makes it a promising candidate for further investigation in drug discovery and development.

The< strong>hydrochloride salt form of this compound enhances its solubility and bioavailability, making it more suitable for pharmaceutical applications. The presence of a methyl group at the 8-position and an azabicyclo framework introduces specific steric and electronic properties that can influence its interactions with biological targets. These features have prompted researchers to explore its potential in various therapeutic areas, including central nervous system (CNS) disorders, inflammation, and pain management.

Recent studies have highlighted the< strong>pharmacological potential of< strong>8-Methyl-8-azabicyclo[3.2.1]octan-3-ol hydrochloride. Research indicates that this compound may exhibit inhibitory effects on certain enzymes and receptors involved in neurological pathways. For instance, preliminary in vitro studies suggest that it could modulate the activity of neurotransmitter receptors such as serotonin and dopamine, which are crucial for regulating mood, cognition, and motor function. These findings align with the growing interest in developing novel therapeutics for conditions like depression, anxiety, and neurodegenerative diseases.

In addition to its potential CNS applications, the< strong>anti-inflammatory properties of this compound have been explored. Chronic inflammation is a hallmark of many diseases, including arthritis, cardiovascular disorders, and certain types of cancer. Preclinical studies have demonstrated that< strong>8-Methyl-8-azabicyclo[3.2.1]octan-3-ol hydrochloride can inhibit key pro-inflammatory cytokines and enzymes, such as cyclooxygenase (COX) and lipoxygenase (LOX). By modulating these pathways, the compound may help reduce inflammation and associated symptoms without the side effects commonly associated with traditional anti-inflammatory drugs.

The< strong>biochemical mechanism of action for< strong>8-Methyl-8-azabicyclo[3.2.1]octan-3-ol hydrochloride is still under investigation, but early findings suggest that it may interact with multiple targets within cellular signaling pathways. The compound’s ability to cross the blood-brain barrier is also an area of active research, as it could facilitate its use in treating neurological conditions directly within the CNS. Furthermore, its stability under various physiological conditions makes it a promising candidate for formulation into oral or injectable medications.

The< strong>synthetic route to< strong>8-Methyl-8-azabicyclo[3.2.1]octan-3-ol hydrochloride involves multi-step organic synthesis techniques that require precise control over reaction conditions to ensure high yield and purity. Researchers have optimized these processes to minimize byproducts and improve scalability for industrial production. Advances in synthetic methodologies have also enabled the introduction of functional groups at specific positions on the bicyclic core, allowing for further customization of the compound’s pharmacological profile.

In conclusion, 8-Methyl-8-azabicyclo[3.2.1]octan-3-ol hydrochloride (CAS No. 258345-27-6) represents a significant advancement in pharmaceutical research due to its unique structural characteristics and potential therapeutic applications.< Strong>This compound holds promise for treating a variety of diseases, particularly those involving neurological dysfunction and chronic inflammation. Ongoing studies aim to elucidate its detailed mechanism of action and explore new synthetic strategies to enhance its efficacy and safety profile.< Strong>The continued investigation into this promising molecule underscores its importance as a valuable asset in the quest for novel pharmacological treatments.

• 41447-16-9((+)-N-Methylallosedridine)
• 120-29-6(Tropine)
• 135-97-7(Pseudotropine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)